Core Viewpoint - The company, JieTe Bio (688026.SH), is focused on providing comprehensive solutions for biological experiments and biopharmaceuticals, with a significant emphasis on biological filtration as an essential component of these processes [1] Group 1: Company Developments - JieTe Bio has previously relied on overseas suppliers for its filtration-related products, but since 2021, the company's actual controller has established JieKe Membrane to develop necessary filtration products [1] - JieKe Membrane has completed foundational research on filtration product technology and has developed several basic products [1] - The company plans to acquire 70% of JieKe Membrane from investors for a total of RMB 7.9199 million, which will make JieKe Membrane a subsidiary and included in the company's consolidated financial statements [1]

人民财讯12月30日电，洁特生物(688026)12月30日公告，拟以1500万元—3000万元回购股份，用于员工 持股计划或股权激励，回购价格不超过25.32元/股。回购资金来源为公司自有资金。 ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-072 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于以集中竞价交易方式回购股份方案的公告 暨回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 相关股东是否存在减持计划：截至本公告日，公司的董事、高级管理人员、控 股股东、实际控制人及一致行动人、持股 5%以上的股东在未来 3 个月、未来 6 个 月内暂未明确是否存在减持公司股份的计划。若上述相关方在回购期间拟实施减 持公司股份计划，公司将严格按照有关法律、法规及规范性文件的相关规定及时 履行信息披露义务。 ● 相关风险提示： 1、本次回购可能存在回购期限内公司股票价格持续超出回购价格上限，进而 导致本次回购方案无法顺利实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、临时经营需要等因素影响， 致使本次回购股份所需资金未能筹措到位，可能存在回购方案无法实施或者部分 实施 ...

南财智讯12月30日电，洁特生物公告，公司拟将募投项目"生物实验室耗材新产品研发项目"达到预定可 使用状态的时间由2025年12月延期至2026年12月。该项目投资总额为4,014.23万元，拟使用募集资金 4,000.00万元，资金来源为2022年向不特定对象发行可转换公司债券的募集资金，主要用于生物实验室 耗材新产品的研发。延期原因为自动化产线建设、新建厂房及洁净车间施工周期较长，导致研发进度不 及预期。为确保研发质量与国际竞争力，公司审慎决定延期。本次延期未改变项目实施主体、投资总额 及用途，不会对募投项目实施造成实质性影响，不存在变相改变募集资金投向和损害股东利益的情形， 对公司正常生产经营无重大不利影响，符合公司长期发展规划。 ...

洁特生物公告，公司拟向广州拓展投资管理有限公司、袁建华、Yuan Ye James、Dannie Yuan合计收购 广东洁科膜分离技术有限公司70%股权，交易金额为人民币791.99万元。本次交易完成后，公司将直接 持有洁科膜70%股权，洁科膜将成为公司的控股子公司，纳入公司合并报表范围。本次交易对手方包含 公司控股股东袁建华及其一致行动人，本次交易构成关联交易，但不构成《上市公司重大资产重组管理 办法》规定的重大资产重组。 ...

Group 1 - A new company named Zhong Sai Bai Tai Biotechnology (Hangzhou) Co., Ltd. has been established, focusing on artificial intelligence application software development [1] - The company's business scope also includes general mechanical equipment installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biological (688026) and other stakeholders [1]

Core Viewpoint - Recently, Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. was established, focusing on artificial intelligence application software development and other related services [1] Company Summary - Zhongsaibaitai Biotechnology (Hangzhou) Co., Ltd. has a business scope that includes artificial intelligence application software development, general machinery installation services, software outsourcing services, and information system integration services [1] - The company is jointly held by Jiete Biotechnology and other stakeholders [1]

Core Viewpoint - The company has decided not to lower the conversion price of its convertible bonds despite triggering the downward adjustment clause due to stock price performance [6][11]. Group 1: Board Meeting Decisions - The fourth board meeting of the company was held on November 21, 2025, with all seven directors present, and the decision was made to not adjust the conversion price of the "Jiet Bio" convertible bonds [1][2]. - The decision was made with a vote of 4 in favor, 0 against, and 0 abstentions [2]. Group 2: Convertible Bond Details - The "Jiet Bio" convertible bonds were issued in 2022, with a total of 4.4 million bonds at a face value of 100 RMB each, raising a total of 440 million RMB [8]. - The initial conversion price was set at 48.23 RMB per share, which has been adjusted multiple times due to various corporate actions [9]. Group 3: Price Adjustment Clause - The downward adjustment clause for the conversion price is triggered when the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [10]. - As of the announcement date, the stock price had indeed triggered this clause, but the board decided against making any adjustments for the next three months [11].

Group 1 - The core point of the article is that Jiet Biotech (SH 688026) held its 25th meeting of the fourth board of directors on November 21, 2025, via telecommunication, where it reviewed the proposal regarding not adjusting the conversion price of "Jiet Convertible Bonds" [1] - For the year 2024, Jiet Biotech's revenue composition is as follows: consumables account for 95.02% of total revenue, while other businesses account for 4.98% [1] - As of the report date, Jiet Biotech has a market capitalization of 2.4 billion yuan [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-068 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于不向下修正"洁特转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、转股价格调整/修正依据 （一）"洁特转债"基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，广州洁特生物过滤股份有限公司（以下简称"公司"）向不特定对象共计发 行 440.00 万张，每张面值为人民币 100 元，按面值发行。本次发行合计募集资 金人民币 44,000.00 万元。经上海证券交易所《自律监管决定书》（[2022]203 号 文）同意，公司 44,000.00 万元可转换公司债券已于 2022 年 8 月 2 日起在上海证 券交易所挂牌交易，债券简称"洁特转债"，债券代码"11 ...